TNF inhibitor

ICYMI: Update on Axial SpA at EULAR 2022

Save

This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.

What Worries You, Masters You (7.1.2022)

Save

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com.  Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.

1. 
   

   FDA approved Abbvies risakizumab-rzaa

Novel Anti-TNF Shines in Rheumatoid Arthritis Trial

Save

A new way of inhibiting tumor necrosis factor (TNF) for treating rheumatoid arthritis showed strong results in a phase II/III clinical trial, researchers said.

About 75% to 80% of patients receiving an investigational agent called ozoralizumab achieved 20% reductions in symptoms by

Two Week Twitter (6.17.2022)

Save

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.

1. 
   

   Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast

Not All RA Drug Classes Are Created Equal

Save

Clear differences were apparent among the three major types of targeted medications for rheumatoid arthritis (RA) in a large European registry study.

For one, patients using inhibitors of the Janus-associated kinase (JAK) pathway were more likely to stop them because of adverse

JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?

Save

Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. 

Spondyloarthritis and COVID-19

Save

There are still questions surrounding COVID-19, and some common questions I receive from patients revolve around what to do with their current DMARDs or should they even start treatment during this pandemic. Two studies focused on this question. 

ACR Applauds FTC Decision to Investigate PBM's

Save

The American College of Rheumatology applauds the Federal Trade Commission’s decision to investigate the business practices of pharmacy benefit managers (PBMs), which continue to increase PBM profit margins while placing the burden of skyrocketing drug costs on America’s most vulnerable

CV risk factors not equal when considering magnitude of risk

Save

What can we learn from Oral Surveillance?

The Oral Surveillance trial has almost become a household word for rheumatologists.

To recap, it was an FDA-mandated, open-label, randomized controlled trial that had high CV risk patients with active RA, on background stable dose

Time to consider gender stratification in AxSpA diagnosis and management

Save

Differences across genders in many aspects related to rheumatic diseases diagnosis, phenotyping, trajectories definition and prediction of response to treatment have been overlooked. Two abstracts have shed light on relevant gender-based differences in AxSpA assessment or treatment.

Update on Axial SpA at EULAR 2022

Save

This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.

Malignancy risk on b/tsDMARDs in patients with prior malignancy history

Save

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic medications and malignancy risk has been largely reassuring, clinical trials have often excluded